Why the next breakthroughs in healthy aging may come from the animal kingdom’s overlooked outliers, and from a rat with a genetic twist.
John Hancock and MIT AgeLab’s second index finds no change since 2025, with care the weakest area and community the strongest ...
Latus Bio's Nature Communications paper models how lowering MSH3 could slow somatic instability – and buy years, perhaps decades.
Fractyl’s Revita hit its six-month goal in a sham-controlled pivotal trial, and the FDA filing is planned for late Q4 2026.
Twelve abstracts head to The Liver Meeting, including a real-world comparison with resmetirom and four on investigational efruxifermin.
Steven Austad and Arlan Richardson explore animal longevity, fasting, GLP-1s and biomarkers to reveal what could translate to ...
Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...
Swiss fertility heavyweight bets on stem-cell-derived egg maturation – and on ovarian biology as a market worth owning.
Prenuvo and UT Dallas researchers found links between sleep efficiency, visceral fat and brain volume, with long sleepers ...
The Boston company says the deal more than doubles its patient reach and opens a path to brain-based sleep testing in primary care from 2027.
United Therapeutics will test treprostinil SMI in about 40 patients with pulmonary hypertension linked to COPD.
A Biograph study using AI on routine heart CT scans found inflammation that cholesterol tests and risk calculators could not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results